Outcomes in patients with PTCL. (A) Five-year OS rates (Kaplan-Meier estimates) stratified by PTCL subtype and ALK status only (current WHO classification). (B) Five-year OS rates with ALK-negative ALCL stratified by genetic subtype. ALK-pos ALCL, anaplastic lymphoma kinase–positive anaplastic large cell lymphoma; ALK-neg DUSP22 ALCL, anaplastic lymphoma kinase–negative DUSP22-rearranged anaplastic large cell lymphoma; ALK-neg TP63 ALCL, anaplastic lymphoma kinase–negative TP63-rearranged anaplastic large cell lymphoma; −/−/− ALCL, triple-negative anaplastic large cell lymphoma (negative for ALK, DUSP22, and TP63).